GS-441524

A nucleoside analog antiviral drug

GS-441524

GS-441524 is a nucleoside analog antiviral drug that has been studied for its potential use in treating viral infections, particularly those caused by coronaviruses. It is a prodrug of remdesivir, which is an antiviral medication used to treat COVID-19.

Chemical structure and properties

Skeletal structure of GS-441524

GS-441524 is a nucleoside analog, meaning it mimics the structure of natural nucleosides, which are the building blocks of nucleic acids like RNA and DNA. The chemical structure of GS-441524 allows it to interfere with the replication of viral RNA, thereby inhibiting the proliferation of the virus within the host organism.

Mechanism of action

GS-441524 works by incorporating itself into the viral RNA chain during replication. This incorporation leads to premature termination of the RNA chain, effectively halting the replication process of the virus. This mechanism is similar to that of other nucleoside analogs, which are commonly used in antiviral therapies.

Clinical applications

While GS-441524 itself is not approved for human use, its prodrug, remdesivir, has been authorized for emergency use in the treatment of COVID-19. GS-441524 has been studied in various animal models and has shown promise in treating infections caused by feline coronavirus, which can lead to feline infectious peritonitis (FIP), a fatal disease in cats.

Research and development

Research into GS-441524 has primarily focused on its efficacy and safety in treating viral infections. Studies have demonstrated its potential in inhibiting the replication of various coronaviruses, including those responsible for SARS and MERS. Ongoing research aims to further understand its pharmacokinetics and potential applications in human medicine.

Related pages

• Remdesivir
• Nucleoside analog
• Antiviral drug
• Coronavirus